Navigation Links
Thomson Reuters Adds Routes of Synthesis Data to Its Newport Horizon Premium and Newport Vision Premium Solutions
Date:6/4/2008

LONDON and PHILADELPHIA, June 5 /PRNewswire/ -- Thomson Reuters, the world's leading source of intelligent information for businesses and professionals, today announced the addition of Prous Science routes of synthesis (ROS) data to the Newport Horizon Premium and Newport Vision Premium solutions. An ROS focused search allows users to identify active pharmaceutical ingredients (APIs) according to an intermediate or reagent used, number of available routes or by patents referenced in a given route. Provided free of charge to current subscribers of the Premium systems, this new dataset, which provides an exciting compliment to the kilogram demand data released in March, enhances product targeting, business development and competitive intelligence by helping users to understand better the chemistry and manufacture of APIs.

The true or original manufacturing process used for a particular API is usually well protected by patents, making it challenging to devise equivalent, cheaper or more efficient processes without infringing on the originator's intellectual property. The new dataset will help to remedy this by providing extensive information for more than 2,500 APIs, consisting of:

-- Full chemical name

-- CAS number

-- Synthesis route diagram

-- Text commentary (with each step indexed to the diagram)

-- Patent references (linked to the patent page)

-- Intermediate chemicals and CAS numbers

-- Reagent chemicals and CAS numbers

-- Scientific journal references

"Understanding the 'recipe' of how a particular active ingredient is made -- or could be made -- is of vital importance to API manufacturers, generic companies and innovators," said Mike Chace-Ortiz, Senior Director, Product Strategy, Thomson Reuters. "By providing access to this important data, Newport Horizon Premium and Newport Vision Premium now allow our customers to gauge which patents are involved, what raw materials are needed, the cost and complexity of the process and whether specialized equipment or facilities must be bought or constructed."

For further information on Thomson Reuters API Intelligence solutions, visit: http://scientific.thomsonreuters.com/newport/

About Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries. For more information, go to http://www.thomsonreuters.com.


'/>"/>
SOURCE Thomson Reuters
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. The Scientific Business of Thomson Reuters Publishes Pharma Matters - a Series of Reviews Covering Various Aspects of the Pharmaceutical Pipeline
2. Thomson Reuters Honors Temple University Health System for Initiative That Cut Costs $64 Million and Grew Clinical Service Lines
3. New Thomson Reuters Biomarkers Report Shines a Light on Revolutionary New Area of Drug Development
4. Thomson Healthcare Undertakes Medical Staff Development Project for IASIS Healthcare
5. Thomson Scientific To Honor Australias Top Researchers With Dedicated Australian Research Day
6. Thomson Healthcare Announces Enhancements to Order Sets Solution
7. Thomson Healthcares Clinical Xpert Navigator Tops KLAS Annual Performance Ranking in Mobile Data Systems for Sixth Consecutive Year
8. Thomson Scientific Introduces a New Quarterly Report Identifying the Movers and Shakers in the U.S. Generics Industry
9. Jobson Medical Information LLC Acquires CenterWatch and New England IRB From Thomson Healthcare
10. Saint Barnabas Health Care System Expands Business Relationship with Thomson Healthcare
11. Protalix BioTherapeutics prGCD Named One of the Five Most Promising Drugs Entering Phase III Trials by Thomson Scientific
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, and ... in the eye of the beholder, according to experts who offered insights and commentary ... of Managed Care. For the full issue, click here . , For the ...
(Date:6/26/2016)... ... , ... PawPaws brand pet supplements owned by Whole Health Supply ... health of felines. The formula is all-natural and is made from Chinese herbs that ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root ...
(Date:6/25/2016)... Washington, D.C. (PRWEB) , ... June 25, 2016 ... ... will discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June ... share their work on several important health care topics including advance care planning, ...
(Date:6/25/2016)... ... , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize ... Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into ... Simply select a ProHand generator and drag it above media or text in the ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
(Date:6/24/2016)... According to a new market ... Needles, Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, ... of Purchase (Retail, Non-Retail) - Trends & Global Forecasts ... market for the forecast period of 2016 to 2021. ... by 2021 from USD 1.65 Billion in 2016, growing ...
Breaking Medicine Technology: